GSK plc
Congressional Trades
Whale Activity
- Increased1
- New0
- Held0
- Decreased0
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| Parrish Capital LLC | 30.9K | $1.5M | increased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
No insider transactions on record.
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Dodge & Cox Stock Fund Dodge & Cox Funds | 35.6M | $1.86B | 1.58% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund Fidelity Rutland Square Trust II | 7.8M | $393.6M | 0.16% | May 31, 2026 |
| Fidelity Series Large Cap Stock Fund Fidelity Hastings Street Trust | 4.6M | $240.1M | 0.83% | Jun 30, 2026 |
| Fidelity Series Value Discovery Fund Fidelity Devonshire Trust | 4.1M | $213.8M | 1.21% | Jul 31, 2026 |
| Dodge & Cox Balanced Fund Dodge & Cox Funds | 3.6M | $188.7M | 1.28% | Jun 30, 2026 |
| Fidelity Growth and Income Portfolio Fidelity Securities Fund | 3.4M | $177.8M | 1.19% | Jul 31, 2026 |
| T. Rowe Price International Value Equity Fund T. ROWE PRICE INTERNATIONAL FUNDS, INC. | 2.6M | $136.4M | 0.80% | Jul 31, 2026 |
| Fidelity Equity Dividend Income Fund Fidelity Financial Trust | 2.7M | $134.7M | 1.67% | May 31, 2026 |
| Select Pharmaceuticals Portfolio Fidelity Select Portfolios | 2.4M | $122.6M | 8.17% | May 31, 2026 |
| Bridge Builder Large Cap Value Fund Bridge Builder Trust | 1.9M | $98.4M | 0.34% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list GSK's shares (CUSIP 37733W204), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Corporate Lobbying
- CHECKMATE GOVERNMENT RELATIONSGSK · 2026 Q2 · HCR, PHA$60K
Filing ↗ - CHECKMATE GOVERNMENT RELATIONSGSK · 2026 Q1 · HCR, PHA$60K
Filing ↗ - CHECKMATE GOVERNMENT RELATIONSGSK · 2025 Q4 · HCR, PHA$50K
Filing ↗ - CHECKMATE GOVERNMENT RELATIONSGSK · 2025 Q3 · HCR, PHA$50K
Filing ↗ - CHECKMATE GOVERNMENT RELATIONSGSK · 2025 Q2 · HCR, PHA$50K
Filing ↗
Government Contracts
No federal contract awards found for GSK plc.
U.S. Patents
No USPTO patent applications found for GSK plc.
Annual Financials
No annual XBRL figures on record for GSK. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
- 4-for-5Reverse splitJul 19, 2022
- 2-for-1Stock splitNov 12, 1991
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
No 8-K filings on record.